Related Experiment Video
Updated: Aug 25, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Treatment of children with familial hypercholesterolemia
1Department of Preventive Cardiology, Preventive Medicine Clinic, Ullevål University Hospital, Oslo, Norway. serena.tonstad@ulleval.no
Insights
Heterozygous familial hypercholesterolemia is common in children, leading to high cholesterol. Statins show promise in lowering LDL-cholesterol and improving endothelial function in pediatric patients.
Area of Science:
- Pediatrics
- Cardiology
- Genetics
Background:
- Familial hypercholesterolemia (FH) affects 1 in 500 individuals, being the primary cause of severe hypercholesterolemia in children.
- Early-onset coronary events, particularly in males under 30, highlight the urgency of pediatric lipid management.
- Dietary interventions show limited efficacy and compliance challenges in pediatric populations.
Purpose of the Study:
- To evaluate the efficacy and safety of statin therapy in pediatric patients with familial hypercholesterolemia.
- To assess the impact of statins on low-density lipoprotein (LDL)-cholesterol levels and endothelial function in children.
- To determine the need for longer-term studies on statin effects on growth and development in prepubertal children.
Main Methods:
- Review of clinical trials investigating statin use in children with familial hypercholesterolemia.
- Analysis of data on LDL-cholesterol reduction and endothelial function restoration.
- Assessment of reported clinical adverse effects and impact on growth and development.
Main Results:
- Statins effectively reduce LDL-cholesterol levels in children.
- One study demonstrated statin-induced restoration of endothelial dysfunction without adverse effects.
- Longer trials are necessary to fully evaluate drug effects on growth, especially in prepubertal children.
Conclusions:
- Statins are effective in lowering LDL-cholesterol in children with familial hypercholesterolemia.
- Risk stratification using gender, family history, and LDL-cholesterol levels is crucial for identifying high-risk children.
- Pediatric patients with very high risk may benefit from initiating statin therapy post-puberty.
Abstract:
Heterozygous familial hypercholesterolemia affects one in every 500 persons and is the most common cause of markedly elevated cholesterol levels in children. Some male patients experience their first coronary event before the age of 30 years. Although dietary measures prevent atherosclerosis in adult populations, the effect of diet on children's lipid levels is limited and compliance is difficult. Trials lasting up to 2 years have shown that statins effectively lower low density lipoprotein (LDL)-cholesterol levels and in one study, restored endothelial dysfunction in children with no clinical adverse effects. To fully assess the effect of drugs on growth and development, especially in prepubertal children, longer trials are required. Gender, family history and LDL-cholesterol level can be used to stratify risk of coronary heart disease. Children that carry very high risk may benefit from starting statins after puberty.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Lipids: Dietary Sources and Requirements
Pharmacogenomics: Identification of New Drug Targets
Atherosclerosis IV: Nursing Management
